Company intelligence / Profile preview

Trium Capital

London, United Kingdomtrium-capital.com ↗

Ownership: Private
Employees: ~84
Development stage: Other

Overview

Trium Capital does not have clinical results as it is an asset manager and does not conduct clinical trials or drug development. As an investor, it has been involved in shareholder activism, notably regarding Acelyrin’s proposed merger with Alumis, arguing for liquidation instead.

Industry: Investors

Partnerships

Portfolio managersExternal fund managers

Beyond the preview

Go deeper on Trium Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trium Capital.

Explore the full profile